Related Experiment Videos
Translating data on antihypertensive drugs into clinical practice
1Department of Medicine, The Brookdale University Hospital and Medical Center, Brooklyn, New York 11212, USA.
Insights
Controlling hypertension remains challenging due to patient adherence and physician goals. New antihypertensive drugs are needed to improve blood pressure control and reduce cardiovascular events.
Area of Science:
- Cardiology
- Pharmacology
- Vascular Biology
Background:
- Hypertension treatment faces two key challenges: inadequate blood pressure control in most patients and insufficient reduction of major clinical endpoints like coronary events and renal failure with traditional therapies.
- Improved understanding of vascular biology highlights the need to address metabolic risk factors (Hypertension Syndrome) and inhibit vascular wall proliferation.
- The renin-angiotensin system is a key focus, with Angiotensin Converting Enzyme inhibitors and Angiotensin Receptor Blockers showing potential, though definitive hypertension trial data is pending.
Purpose of the Study:
- To highlight the persistent challenges in hypertension management.
- To discuss the limitations of current antihypertensive therapies in preventing major cardiovascular and renal events.
- To explore emerging therapeutic strategies targeting vascular biology and the Hypertension Syndrome.
Main Methods:
- Review of current understanding of hypertension treatment challenges.
- Analysis of the role of vascular biology and metabolic factors in hypertension.
- Evaluation of existing and emerging antihypertensive drug classes and their potential benefits.
Main Results:
- Traditional antihypertensive regimens, including diuretics, offer protection against stroke and heart failure but not fully against coronary events or renal failure.
- Newer drug classes like ACE inhibitors, ARBs, and calcium channel blockers show promise in cardiovascular protection, but definitive endpoint data in hypertension trials are still awaited.
- Physicians face a dilemma in choosing between established therapies with known limitations and newer agents with unproven long-term benefits in hypertension.
Conclusions:
- Significant unmet needs exist in achieving optimal blood pressure control and reducing major adverse cardiovascular and renal outcomes in hypertensive patients.
- Further research and ongoing prospective trials are crucial to guide optimal antihypertensive drug selection.
- A comprehensive approach addressing vascular biology, metabolic factors, and novel therapeutic agents is necessary for improved hypertension management.
Abstract:
Two problems in the treatment of hypertension continue to be largely unsolved. The first, and more simple, is our inability to adequately control blood pressure in the majority of hypertensive patients. This not only reflects the difficulty of retaining patients in effective treatment programs, but also of convincing physicians to strive for optimal blood pressure levels. There is a continuing need for new antihypertensive drugs and combinations to help accomplish these goals. The second major problem is that the major clinical endpoints, including coronary events and renal failure, have not been adequately reduced by traditional therapies. Standard regimens, particularly those including diuretics, have protected against strokes and heart failure. Our improved understanding of vascular biology in hypertension has directed interest to the mechanisms in hypertensive patients that might accelerate atherosclerosis and vascular events in these individuals. This involves addressing the concomitant metabolic risk factors that comprise the "Hypertension Syndrome," and, perhaps of equal importance, finding therapies that directly inhibit unwanted types of growth and proliferative activities within the walls of critical arteries. Many substances within the endothelium and the vascular wall may participate as initiators or mediators of pathology, but most information thus far has focused on the renin-angiotensin system. Angiotensin converting enzyme inhibitors (and potentially angiotensin receptor blockers) have provided coronary and renal protection in various cardiovascular conditions, though not yet in formal hypertension trials. Calcium channel blockers have also shown promise, including recent stroke and cardiovascular benefits in patients with isolated systolic hypertension, but, again, definitive coronary data in hypertension are awaited. Unless concomitant conditions mandate the selection of a particular antihypertensive drug class, physicians currently have a dilemma: should they choose drugs from older classes that have not provided full protection? Or, should they prescribe newer agents with exciting potential but with, as yet, unproved endpoint benefits in hypertension? Until currently ongoing prospective trials of antihypertensive therapy are completed, physicians must be guided by their own interpretations of the available data.